FLT3 and acute myeloid leukemia: ELN segregated CN-AML patients based on presence of FLT3-ITD, mutations of NPM1 and CEBPA. After adjusting for the impact of these known risk factors, we performed multivariable analyses to confirm the prognostic significance of RUNX1 expression.